Aflibercept

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Aflibercept is a recombinant fusion protein (VEGF trap) broadly recognised for treating neovascular (wet) age-related macular degeneration, diabetic macular edema, and metastatic colorectal cancer, acting by blocking VEGF-A, VEGF-B, and placental growth factor (PlGF). The TxGNN model assigns its highest prediction score to Esotropia (inward convergent strabismus) at 99.38%, however zero clinical trials and zero publications currently support this specific repurposing direction, and the mechanistic rationale is considered biologically weak.

Quick Overview

Item	Content
Original Indication	Neovascular (wet) AMD, diabetic macular edema, macular edema following retinal vein occlusion, metastatic colorectal cancer (general knowledge; no ARTG entry data available in current evidence pack)
Predicted New Indication	Esotropia
TxGNN Prediction Score	99.38%
Evidence Level	L5
Australia Market Status	No ARTG registration found — data requires manual TGA verification
Number of ARTG Entries	0 (per current dataset — see note below)
Recommended Decision	Hold

⚠️ Data Quality Note: This evidence pack carries candidate ID TW-DB08885-multi and appears to contain Taiwan regulatory data rather than Australian TGA/ARTG data. Aflibercept (Eylea®) is widely understood to hold regulatory approval in multiple high-income countries. Australian healthcare professionals should independently verify current ARTG registration status at TGA ARTG Public Summary.

Why is This Prediction Reasonable?

Aflibercept functions as a recombinant “VEGF trap” — a fusion protein combining the ligand-binding domains of VEGFR-1 and VEGFR-2 with the Fc portion of human IgG1. By acting as a high-affinity decoy receptor, it binds and neutralises VEGF-A, VEGF-B, and PlGF, thereby blocking downstream angiogenesis signalling. This mechanism underlies its efficacy across neovascular retinal diseases and VEGF-dependent tumours.

Esotropia, by contrast, is a form of strabismus characterised by inward deviation of one or both eyes. The primary aetiology involves imbalance of the extraocular muscles or aberrant neuromuscular innervation — neither of which has a recognised direct connection to the VEGF signalling axis. The repurposing rationale analysis in this evidence pack concludes that the TxGNN high score most likely reflects an indirect knowledge graph connection through shared “ophthalmic disease” nodes, rather than genuine mechanistic overlap.

The sole theoretical bridge between Aflibercept and esotropia comes from an adverse event observation: premature infants who develop retinopathy of prematurity (ROP) and receive intravitreal anti-VEGF therapy (including Aflibercept) have a documented higher rate of subsequent strabismus development. This represents a treatment complication, not a therapeutic mechanism — and it argues against, not for, using Aflibercept to treat esotropia.

Clinical Trial Evidence

No clinical trials specifically investigating Aflibercept for esotropia are currently registered.

Currently no related clinical trials registered.

Literature Evidence

No publications specifically investigating Aflibercept for esotropia are currently indexed.

Currently no related literature available.

Australia Market Information

No ARTG registration data was retrieved for Aflibercept in this evidence pack. Manual verification against the TGA ARTG is required before any clinical or regulatory decision-making.

Currently no ARTG entries available in this dataset. Please verify directly at www.tga.gov.au/resources/artg.

Cytotoxicity

Aflibercept (as Zaltrap®) is approved for use in metastatic colorectal cancer (mCRC) in combination with FOLFIRI chemotherapy. It meets the antineoplastic criteria (antiangiogenic mechanism; oncology-approved indication).

Item	Content
Cytotoxicity Classification	Targeted therapy — antiangiogenic VEGF trap (biologic; not a conventional cytotoxic agent)
Myelosuppression Risk	Low as monotherapy; High when combined with FOLFIRI (neutropenia and leukopenia are dose-limiting in the mCRC regimen — monitor closely)
Emetogenicity Classification	Low
Monitoring Items	Full blood count (FBC) with differential, liver function tests, renal function, urinalysis (proteinuria), blood pressure
Handling Protection	As a biologic agent, standard aseptic preparation precautions apply; not classified as a conventional cytotoxic requiring specialised cytotoxic handling suite, but facility-specific policies should be followed

Safety Considerations

No safety data (key warnings, contraindications, or drug interactions) was available in this evidence pack. All fields returned as data gaps.

Please refer to the TGA-approved Product Information (PI) for Eylea® (ophthalmic use) and/or Zaltrap® (oncology use) for complete safety information. PI documents are available via the TGA website.

Predicted Indication Summary: All Candidates

The TxGNN model generated 10 candidate repurposing indications for Aflibercept. All carry an L5 evidence level (model prediction only) with no supporting clinical or preclinical studies retrieved. A brief mechanistic quality assessment is provided below:

Rank	Indication	Score	Mechanistic Rationale Quality	Recommendation
1	Esotropia	99.38%	❌ No VEGF link — likely KG artefact	Hold
2	Esophageal varices (without bleeding)	97.56%	✅ Biologically plausible — VEGF drives portal hypertension neovascularisation	Research Question
3	Esophageal varices (with bleeding)	97.56%	⚠️ Plausible mechanism but acute haemorrhage setting raises serious safety concerns	Hold
4	Varicose disease	96.95%	⚠️ Partial match — VEGF-A/B role in venous remodelling; VEGF-C/D (via VEGFR3) not blocked by Aflibercept	Research Question
5	Urethral calculus	95.97%	❌ No VEGF link — likely KG artefact	Hold
6	Adenosine deaminase deficiency	95.76%	❌ Metabolic/genetic disease; no VEGF connection	Hold
7	Hemorrhagic disease of newborn	95.56%	❌ Vitamin K deficiency mechanism; no VEGF connection	Hold
8	Ectomesenchymoma	94.52%	✅ Tumour angiogenesis VEGF mechanism applicable (ultra-rare tumour)	Research Question
9	Malignant cutaneous granular cell skin tumour	94.51%	✅ Soft tissue sarcoma — VEGF/PlGF mechanism plausible	Research Question
10	Middle ear neuroendocrine tumour	94.42%	✅ Highly vascular NET; consistent with anti-VEGF class mechanism	Research Question

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked TxGNN prediction (esotropia at 99.38%) lacks any credible mechanistic basis, has zero supporting clinical trials or publications, and the biological connection most likely reflects a knowledge graph artefact rather than genuine pharmacological insight. A “Hold” decision is appropriate for the primary predicted indication.

Before this candidate can progress, the following is needed:

Verify Australian market status: Confirm current ARTG registration for Eylea® and Zaltrap® directly via TGA ARTG to resolve the data gap in this evidence pack
Retrieve Aflibercept MOA data from DrugBank (DG002): Required to complete mechanistic rationale analysis across all 10 predicted indications
Retrieve TGA Product Information warnings and contraindications (DG001): Blocking data gap that prevents safety pre-screening
Re-evaluate Rank 2 (Esophageal Varices without Bleeding): This is the most biologically plausible indication — a targeted literature search and exploratory review of portal hypertension animal model data is recommended as a priority next step
Prioritise oncology candidates (Ranks 8–10): Ectomesenchymoma, malignant granular cell tumour, and middle ear NET all share mechanistic overlap with Aflibercept’s approved oncology mechanism; rare disease orphan pathways may be worth exploring

This report is generated for research purposes only and does not constitute medical advice. All repurposing candidates require prospective clinical validation before therapeutic application. For clinical decisions, refer to TGA-approved Product Information.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.